Literature DB >> 21632271

Lrrk2 p.Q1111H substitution and Parkinson's disease in Latin America.

Ignacio F Mata1, Greggory J Wilhoite, Dora Yearout, Justin A Bacon, Mario Cornejo-Olivas, Pilar Mazzetti, Victoria Marca, Olimpio Ortega, Oscar Acosta, Carlos Cosentino, Luis Torres, Angel C Medina, Carolina Perez-Pastene, Fernando Díaz-Grez, Carles Vilariño-Güell, Pablo Venegas, Marcelo Miranda, Osvaldo Trujillo-Godoy, Luis Layson, Rodrigo Avello, Elena Dieguez, Victor Raggio, Federico Micheli, Claudia Perandones, Victoria Alvarez, Juan Segura-Aguilar, Matthew J Farrer, Cyrus P Zabetian, Owen A Ross.   

Abstract

Mutations in the LRRK2 gene are the most common genetic cause of Parkinson's disease, with frequencies displaying a high degree of population-specificity. Although more than 100 coding substitutions have been identified, only seven have been proven to be highly penetrant pathogenic mutations. Studies however are lacking in non-white populations. Recently, Lrrk2 p.Q1111H (rs78365431) was identified in two affected Hispanic brothers and absent in 386 non-Hispanic white healthy controls. We therefore screened this variant in 1460 individuals (1150 PD patients and 310 healthy controls) from 4 Latin American countries (Peru, Chile, Uruguay and Argentina). In our case-control series from Peru and Chile we observed an increased frequency of Lrrk2 p.Q1111H in patients (7.9%) compared to controls (5.4%) although the difference did not reach significance (OR 1.38; p = 0.10). In addition, the frequency of Lrrk2 p.Q1111H varied greatly between populations and further screening in a set of pure Amerindian and pure Spanish controls suggested that this variant likely originated in an Amerindian population. Further studies in other Latin American populations are warranted to assess its role as a risk factor for Parkinson's disease. Screening in Parkinson's disease patients from under-represented populations will increase our understanding of the role of LRRK2 variants in disease risk worldwide.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21632271      PMCID: PMC3167927          DOI: 10.1016/j.parkreldis.2011.05.003

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  12 in total

1.  A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan.

Authors:  Alessio Di Fonzo; Yah-Huei Wu-Chou; Chin-Song Lu; Marina van Doeselaar; Erik J Simons; Christan F Rohé; Hsiu-Chen Chang; Rou-Shayn Chen; Yi-Hsin Weng; Nicola Vanacore; Guido J Breedveld; Ben A Oostra; Vincenzo Bonifati
Journal:  Neurogenetics       Date:  2006-04-22       Impact factor: 2.660

2.  Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls.

Authors:  Coro Paisán-Ruíz; Priti Nath; Nicole Washecka; J Raphael Gibbs; Andrew B Singleton
Journal:  Hum Mutat       Date:  2008-04       Impact factor: 4.878

3.  Lrrk2 pathogenic substitutions in Parkinson's disease.

Authors:  Ignacio F Mata; Jennifer M Kachergus; Julie P Taylor; Sarah Lincoln; Jan Aasly; Timothy Lynch; Mary M Hulihan; Stephanie A Cobb; Ruey-Meei Wu; Chin-Song Lu; Carlos Lahoz; Zbigniew K Wszolek; Matthew J Farrer
Journal:  Neurogenetics       Date:  2005-09-17       Impact factor: 2.660

4.  LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago.

Authors:  Cyrus P Zabetian; Carolyn M Hutter; Dora Yearout; Alexis N Lopez; Stewart A Factor; Alida Griffith; Berta C Leis; Thomas D Bird; John G Nutt; Donald S Higgins; John W Roberts; Denise M Kay; Karen L Edwards; Ali Samii; Haydeh Payami
Journal:  Am J Hum Genet       Date:  2006-08-17       Impact factor: 11.025

5.  Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease.

Authors:  William C Nichols; Nathan Pankratz; Dena Hernandez; Coro Paisán-Ruíz; Shushant Jain; Cheryl A Halter; Veronika E Michaels; Terry Reed; Alice Rudolph; Clifford W Shults; Andrew Singleton; Tatiana Foroud
Journal:  Lancet       Date:  2005 Jan 29-Feb 4       Impact factor: 79.321

6.  LRRK2 mutations in patients with Parkinson's disease from Peru and Uruguay.

Authors:  Ignacio F Mata; Carlos Cosentino; Victoria Marca; Luis Torres; Pilar Mazzetti; Olimpio Ortega; Victor Raggio; Ruth Aljanati; Ricardo Buzó; Dora Yearout; Elena Dieguez; Cyrus P Zabetian
Journal:  Parkinsonism Relat Disord       Date:  2008-11-05       Impact factor: 4.891

7.  Molecular analyses of the LRRK2 gene in European and North African autosomal dominant Parkinson's disease.

Authors:  S Lesage; C Condroyer; A Lannuzel; E Lohmann; A Troiano; F Tison; P Damier; S Thobois; A-M Ouvrard-Hernandez; S Rivaud-Péchoux; C Brefel-Courbon; A Destée; C Tranchant; M Romana; L Leclere; A Dürr; A Brice
Journal:  J Med Genet       Date:  2009-04-08       Impact factor: 6.318

8.  LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8.

Authors:  W C Nichols; V E Elsaesser; N Pankratz; M W Pauciulo; D K Marek; C A Halter; A Rudolph; C W Shults; T Foroud
Journal:  Neurology       Date:  2007-09-05       Impact factor: 9.910

9.  Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease.

Authors:  Owen A Ross; Yih-Ru Wu; Mei-Ching Lee; Manabu Funayama; Meng-Ling Chen; Alexandra I Soto; Ignacio F Mata; Guey-Jen Lee-Chen; Chiung Mei Chen; Michelle Tang; Yi Zhao; Nobutaka Hattori; Matthew J Farrer; Eng-King Tan; Ruey-Meei Wu
Journal:  Ann Neurol       Date:  2008-07       Impact factor: 10.422

10.  Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease.

Authors:  Alessio Di Fonzo; Cristina Tassorelli; Michele De Mari; Hsin F Chien; Joaquim Ferreira; Christan F Rohé; Giulio Riboldazzi; Angelo Antonini; Gianni Albani; Alessandro Mauro; Roberto Marconi; Giovanni Abbruzzese; Leonardo Lopiano; Emiliana Fincati; Marco Guidi; Paolo Marini; Fabrizio Stocchi; Marco Onofrj; Vincenzo Toni; Michele Tinazzi; Giovanni Fabbrini; Paolo Lamberti; Nicola Vanacore; Giuseppe Meco; Petra Leitner; Ryan J Uitti; Zbigniew K Wszolek; Thomas Gasser; Erik J Simons; Guido J Breedveld; Stefano Goldwurm; Gianni Pezzoli; Cristina Sampaio; Egberto Barbosa; Emilia Martignoni; Ben A Oostra; Vincenzo Bonifati
Journal:  Eur J Hum Genet       Date:  2006-03       Impact factor: 4.246

View more
  4 in total

1.  Structural and functional in silico analysis of LRRK2 missense substitutions.

Authors:  Fernando Cardona; Marta Tormos-Pérez; Jordi Pérez-Tur
Journal:  Mol Biol Rep       Date:  2014-02-02       Impact factor: 2.316

2.  Variable frequency of LRRK2 variants in the Latin American research consortium on the genetics of Parkinson's disease (LARGE-PD), a case of ancestry.

Authors:  Mario Cornejo-Olivas; Luis Torres; Mario R Velit-Salazar; Miguel Inca-Martinez; Pilar Mazzetti; Carlos Cosentino; Federico Micheli; Claudia Perandones; Elena Dieguez; Victor Raggio; Vitor Tumas; Vanderci Borges; Henrique B Ferraz; Carlos R M Rieder; Artur Shumacher-Schuh; Carlos Velez-Pardo; Marlene Jimenez-Del-Rio; Francisco Lopera; Jorge Chang-Castello; Brennie Andreé-Munoz; Sarah Waldherr; Dora Yearout; Cyrus P Zabetian; Ignacio F Mata
Journal:  NPJ Parkinsons Dis       Date:  2017-06-02

Review 3.  Genetics and genomics in Peru: Clinical and research perspective.

Authors:  Heinner Guio; Julio A Poterico; Kelly S Levano; Mario Cornejo-Olivas; Pilar Mazzetti; Gioconda Manassero-Morales; Manuel F Ugarte-Gil; Eduardo Acevedo-Vásquez; Milagros Dueñas-Roque; Alejandro Piscoya; Ricardo Fujita; Cesar Sanchez; Sandro Casavilca-Zambrano; Luis Jaramillo-Valverde; Yasser Sullcahuaman-Allende; Juan M Iglesias-Pedraz; Hugo Abarca-Barriga
Journal:  Mol Genet Genomic Med       Date:  2018-11       Impact factor: 2.183

4.  Novel Variants in LRRK2 and GBA Identified in Latino Parkinson Disease Cohort Enriched for Caribbean Origin.

Authors:  Karen Nuytemans; Farid Rajabli; Parker L Bussies; Katrina Celis; William K Scott; Carlos Singer; Corneliu C Luca; Angel Vinuela; Margaret A Pericak-Vance; Jeff M Vance
Journal:  Front Neurol       Date:  2020-11-12       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.